Journal: Antimicrobial Agents and Chemotherapy

Article Title: Intrinsic Antibacterial Activity of Xeruborbactam In Vitro : Assessing Spectrum and Mode of Action

doi: 10.1128/aac.00879-22

Figure Lengend Snippet: In vitro activity of various BLIs against isogenic strains of Gram-negative bacteria

Article Snippet: Avibactam was purchased from eNovation Chemicals LLC, Bridgewater, NJ, USA; zidebactam was from MedKoo Biosciences, Inc., Morrisville, NC, and nacubactam was from Advanced ChemBlocks, Hayward, CA.

Techniques: In Vitro, Activity Assay, Over Expression

Journal: Antimicrobial Agents and Chemotherapy

Article Title: New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

doi: 10.1128/AAC.00733-19

Figure Lengend Snippet: MIC values of β-lactams with without β-lactamase inhibitors against M. abscessus subsp. abscessus strain ATCC 19977 T in Middlebrook 7H9 medium and CAMHB

Article Snippet: Nacubactam and zidebactam were procured from MedKoo Biosciences, Inc., NC, USA (purity >98%).

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

doi: 10.1128/AAC.00733-19

Figure Lengend Snippet: MIC values of β-lactams with and without nacubactam or zidebactam against 28 drug-resistant MABC clinical isolates in Middlebrook 7H9 medium

Article Snippet: Nacubactam and zidebactam were procured from MedKoo Biosciences, Inc., NC, USA (purity >98%).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: Characteristics of the strains used

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: Estimation of fT >MICi . (a) Simulated free plasma nacubactam PK profile; (b) calculated aztreonam MIC i transition after administration of nacubactam based on the dose–response curve; (c) free plasma aztreonam PK profile (solid orange line) and aztreonam MIC i transition (blue dashed line) were superimposed. The % fT >MICi is the percentage of time that the free plasma aztreonam concentration exceeded the MIC i . This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: Concentration Assay

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: MIC curve between the aztreonam MIC and the nacubactam concentration ( n = 3). (a) NDM-1-positive K. pneumoniae ATCC BAA-2473; (b) IMP-6-positive K. pneumoniae MSC 21664; (c) OXA-48-positive K. pneumoniae MSC 21444.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: Concentration Assay

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: PK profiles of nacubactam (a) and aztreonam (b) in neutropenic mice (mean ± SD, n = 3).

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: In vivo dose-fractionation study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with NDM-1-positive K. pneumoniae ATCC BAA-2473 (mean ± SD, n = 3). Aztreonam was administered every 2 h, and nacubactam was administered with variable frequency: every 2 h, every 4 h and every 8 h.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: In Vivo, Fractionation, Infection

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: In vivo dose-ranging study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with IMP-6-positive K. pneumoniae MSC 21664 (a) and OXA-48-positive K. pneumoniae MSC 21444 (b) (mean ± SD, n = 3). Both nacubactam and aztreonam were administered every 2 h.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: In Vivo, Infection

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: PK/PD analysis and target fT >MICi values of aztreonam with/without nacubactam.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: PK/PD analysis based on fT > C T with optimal C T values of nacubactam (a), f AUC 24 of nacubactam (b), and fC max of nacubactam (c).

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: